AdaptVac ApS

ExpreS2ion Biotechnologies ApS is proud to own a 34% stake in AdaptVac, a pioneering biotechnology company co-founded by ExpreS2ion and NextGen Vaccines in 2017. This strategic ownership aims at leveraging synergies between our platforms and expertise.

The VLP Platform Technology

AdaptVac has developed a cutting-edge virus-like particle (VLP) technology, which can be used as an antigen delivery vehicle to create effective, safe, and scalable vaccines and treatments.

This technology mimics the structure of viruses, eliciting strong immune responses without using live pathogens. The key advantages of the VLP platform include:

Enhanced Immunogenicity: Provides robust and long-lasting immune responses.
Safety: Utilizes non-infectious particles, ensuring safety for the recipients.
Scalability: Facilitates large-scale production to meet global demand.

This platform has demonstrated versatility across various applications, making it a powerful tool in the fight against a wide range of diseases.

Learn More

For more detailed information about AdaptVac’s innovative work, visit their website: AdaptVac ApS.